CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
This Quarter Return
+18.02%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$1.06B
AUM Growth
+$1.06B
(-1.1%)
Cap. Flow
-$150M
Cap. Flow
% of AUM
-14.08%
Top 10 Holdings %
Top 10 Hldgs %
37.54%
Holding
501
New
15
Increased
263
Reduced
171
Closed
24
Top Buys
| 1 |
SPDR Gold Trust
GLD
|
$6.59M |
| 2 |
iShares Gold Trust Micro
IAUM
|
$4.62M |
| 3 |
Intuit
INTU
|
$3.73M |
| 4 |
SPDR Gold MiniShares Trust
GLDM
|
$3.6M |
| 5 |
T-Mobile US
TMUS
|
$2.35M |
Top Sells
| 1 |
Apple
AAPL
|
$17.4M |
| 2 |
NVIDIA
NVDA
|
$12.2M |
| 3 |
Microsoft
MSFT
|
$11.5M |
| 4 |
Amazon
AMZN
|
$8.86M |
| 5 |
Broadcom
AVGO
|
$8.43M |
Sector Composition
| 1 | Technology | 38.15% |
| 2 | Healthcare | 22.68% |
| 3 | Communication Services | 12.64% |
| 4 | Consumer Discretionary | 11.62% |
| 5 | Consumer Staples | 3.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
401
Humacyte
HUMA
$239M
| $65.1K | 0.01% |
31,155
+5,346
| +21% | +$11.2K |
|
402
Exact Sciences
EXAS
$9.09B
| $64.6K | 0.01% |
1,216
+1,000
| +463% | +$53.1K |
|
403
Altimmune
ALT
$331M
| $63K | 0.01% |
16,290
+842
| +5% | +$3.26K |
|
404
Invesco Senior Loan ETF
BKLN
$6.97B
| $62.2K | 0.01% |
+2,972
| New | +$62.2K |
|
405
Corvus Pharmaceuticals
CRVS
$422M
| $62K | 0.01% |
15,488
+2,599
| +20% | +$10.4K |
|
406
Atea Pharmaceuticals
AVIR
$270M
| $61.9K | 0.01% |
17,188
+246
| +1% | +$886 |
|
|
BCYC
407
Bicycle Therapeutics
BCYC
$499M
| $61.6K | 0.01% |
8,866
+33
| +0.4% | +$229 |
|
408
Astria Therapeutics
ATXS
$372M
| $60.8K | 0.01% |
11,335
+15
| +0.1% | +$80 |
|
409
Olema Pharmaceuticals
OLMA
$444M
| $58.5K | 0.01% |
13,742
-1,150
| -8% | -$4.9K |
|
|
ALMS
410
Alumis Inc. Common Stock
ALMS
$485M
| $57.6K | 0.01% |
19,197
+9,725
| +103% | +$29.2K |
|
411
Vanda Pharmaceuticals
VNDA
$278M
| $55.9K | 0.01% |
11,837
+140
| +1% | +$661 |
|
|
SLN
412
Silence Therapeutics
SLN
$225M
| $54.8K | 0.01% |
9,446
+14
| +0.1% | +$81 |
|
413
Cartesian Therapeutics
RNAC
$256M
| $54.2K | 0.01% |
5,213
+115
| +2% | +$1.2K |
|
414
Rocket Pharmaceuticals
RCKT
$350M
| $53K | 0.01% |
21,639
+251
| +1% | +$615 |
|
415
Annexon
ANNX
$227M
| $52.9K | 0.01% |
22,036
+655
| +3% | +$1.57K |
|
416
Alpha Teknova
TKNO
$226M
| $52.7K | 0.01% |
10,733
+40
| +0.4% | +$196 |
|
417
Foghorn Therapeutics
FHTX
$298M
| $52.6K | 0.01% |
11,195
+40
| +0.4% | +$188 |
|
418
Entrada Therapeutics
TRDA
$205M
| $51.2K | ﹤0.01% |
7,623
+82
| +1% | +$551 |
|
|
CMPS
419
Compass Pathways
CMPS
$434M
| $51.2K | ﹤0.01% |
18,272
+5,817
| +47% | +$16.3K |
|
420
Allogene Therapeutics
ALLO
$249M
| $49.6K | ﹤0.01% |
43,931
+1,874
| +4% | +$2.12K |
|
|
THRD
421
DELISTED
Third Harmonic Bio
THRD
| $49.2K | ﹤0.01% |
9,064
+26
| +0.3% | +$141 |
|
422
MaxCyte
MXCT
$143M
| $46.6K | ﹤0.01% |
21,354
+196
| +0.9% | +$427 |
|
423
Tevogen Bio Holdings
TVGN
$175M
| $46.2K | ﹤0.01% |
36,934
+1,822
| +5% | +$2.28K |
|
424
Neurogene
NGNE
$280M
| $42.8K | ﹤0.01% |
2,864
-116
| -4% | -$1.73K |
|
425
OmniAb
OABI
$227M
| $42.8K | ﹤0.01% |
24,571
+298
| +1% | +$519 |
|